Apolomics在符合列名规则后留在Nasdaq, 避免了除名听证会。 Apollomics stays on Nasdaq after meeting listing rules, avoiding delisting hearing.

阿波罗米克公司(APLM)在交易所确定该公司符合继续列名的要求后,将保留在Nasdaq上,取消先前排定的关于其就除名通知提出上诉的听证会。 Apollomics Inc. (APLM) will remain listed on Nasdaq after the exchange determined the company complies with continued listing requirements, canceling a previously scheduled hearing on its appeal of a delisting notice. 以肿瘤治疗为重点的生物制药公司正在推进其领先的药物候选者vebreltinib(APL-101)、一种C-Met抑制剂(C-Met抑制剂),这是对非小细胞肺癌和具有C-Met改变作用的其他高级肿瘤的第二阶段试验。 The biopharmaceutical firm, focused on oncology treatments, is advancing its lead drug candidate vebreltinib (APL-101), a c-Met inhibitor, in a Phase 2 trial for non-small cell lung cancer and other advanced tumors with c-Met alterations. 发布稿中的前瞻性说明受到证交会申报中概述的风险和不确定因素的影响。 Forward-looking statements in the release are subject to risks and uncertainties outlined in its SEC filings.